Download PDF
CC BY 4.0 · Rev Bras Ginecol Obstet 2018; 40(10): 593-598
DOI: 10.1055/s-0038-1670713
Original Article
Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Negative Correlation between Placental Growth Factor and Endocan-1 in Women with Preeclampsia

Correlação negativa entre fator de crescimento placentário e endocan-1 em mulheres com pré-eclâmpsia
Marta Ribeiro Hentschke
1   Laboratory of Nephrology, Hospital São Lucas, School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
,
Edson Vieira da Cunha Filho
1   Laboratory of Nephrology, Hospital São Lucas, School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
,
Matias Costa Vieira
1   Laboratory of Nephrology, Hospital São Lucas, School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
,
Letícia Germany Paula
1   Laboratory of Nephrology, Hospital São Lucas, School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
,
Hiten D. Mistry
2   Division of Child Health, Obstetrics & Gynecology, University of Nottingham, Nottingham, United Kingdom
,
Bartira Ercília Pinheiro da Costa
1   Laboratory of Nephrology, Hospital São Lucas, School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
,
Carlos Eduardo Poli-de-Figueiredo
1   Laboratory of Nephrology, Hospital São Lucas, School of Medicine, Pontifícia Universidade Católica do Rio Grande do Sul, Porto Alegre, RS, Brazil
› Author Affiliations
Further Information

Publication History

05 February 2018

02 July 2018

Publication Date:
23 October 2018 (online)

   Permissions and Reprints

Abstract

Objective To analyze endocan-1, a biomarker of vascular endothelial related pathologies, and the placental growth factor (PlGF), an angiogenic factor and a placental dysfunction marker in patients with preeclampsia (PE).

Methods Case-control study conducted at Hospital São Lucas, in the city of Porto Alegre, Brazil. Endocan-1 and PlGF levels were quantified in the maternal plasma using the MagPlexTH-C microsphere system (MAGPIX System, Luminex, Austin, Texas, US) and evaluated through analysis of covariance (ANCOVA) and adjusted by body mass index (BMI), gestational age and maternal age. To estimate the difference between the groups, the mean ratio (MR) and the 95% confidence interval (95%CI) were calculated. The Pearson correlation test was used to establish any association between endocan-1 and PlGF levels. The null hypothesis was rejected when p < 0.05.

Results The group of patients was composed by normotensive (n = 67) patients and patients with PE (n = 50). A negative correlation between endocan-1 and the PlGF was noted in the entire normotensive group (linear correlation coefficient [r] = −0.605; p < 0.001), as well as in the PE group (r = −0.545; p < 0.001).

Conclusion Endocan-1 levels are increased in patients with PE, and are inversely correlated with PlGF levels. We suggest that it is important to analyze angiogenic and proinflammatory molecules concomitantly in women with PE to better understand the pathophysiology of the disease. Both molecules are strong candidates for PE biomarkers, and future studies will examine any mechanisms connecting these factors in PE.

Resumo

Objetivo Analisar o endocan-1, um biomarcador de patologias vasculares endoteliais, e o fator de crescimento placentário (FCPl), um fator angiogênico, marcador de disfunção placentária em pacientes com pré-eclâmpsia (PE).

Métodos Estudo de caso-controle realizado no Hospital São Lucas, em Porto Alegre. Os níveis de endocan-1 e FCPl foram quantificados no plasma materno usando o sistema de microesferas MagPlexTH-C (MAGPIX System, Luminex, Austin, Texas, US) e analisados por análise de covariância (ANCOVA) e ajustados por índice de massa corporal (IMC), idade gestacional e idade materna. Para calcular a diferença entre os grupos, utilizou-se a razão das médias (RM) e o intervalo de confiança de 95% (IC95%). O teste de correlação de Pearson foi utilizado para estabelecer a associação entre os níveis de endocan-1 e FCPl. A hipótese nula foi rejeitada quando p < 0,05.

Resultados O grupo de pacientes foi composto por pacientes normotensas (n = 67) e pacientes com PE (n = 50). Uma correlação negativa entre o endocan-1 e o FCPl foi observada em todo o grupo de pacientes normotensas (coeficiente de correlação linear [r] = −0,605; p < 0,001), bem como no grupo com PE (r = −0,545; p < 0,001).

Conclusão Os níveis de endocan-1 estão aumentados em pacientes com PE e inversamente correlacionados com os níveis de FCPl. Sugerimos a importância de analisar moléculas angiogênicas e pró-inflamatórias concomitantemente em mulheres com PE para compreender melhor a fisiopatologia da doença. Ambas as moléculas são fortes candidatos a serem considerados biomarcadores de PE, e trabalhos futuros poderão avaliar quaisquer mecanismos que liguem esses fatores na PE.

Keywords

pregnancy-induced hypertension - preeclampsia - endothelial function - biomarkers - cytokines

Palavras-chave

hipertensão induzida pela gravidez - pré-eclâmpsia - função endotelial - biomarcadores - citocinas

Contributions

Marta Ribeiro Hentschke: substantial contributions to conception and design, data collection and analysis, and interpretation of data. Edson Vieira Cunha Filho: interpretation of data; critical review of the intellectual content; final approval of the version to be published. Matias Costa Vieira: interpretation of data; critical review of the intellectual content; final approval of the version to be published. Letícia Germany Paula: interpretation of data; critical review of the intellectual content. Hiten Mistry: substantial contributions to conception and design and interpretation of data; critical review of the intellectual content; final approval of the version to be published. Bartira Ercília Pinheiro da Costa: substantial contributions to conception and design, data collection and analysis, and interpretation of data; writing of the article or critical review of the intellectual content; and final approval of the version to be published. Carlos E. Poli-de-Figueiredo: substantial contributions to conception and design, data analysis, and interpretation of data; writing of the article or critical review of the intellectual content; final approval of the version to be published.


 

  • References

  • 1 Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009; 33 (03) 130-137 . Doi: 10.1053/j.semperi.2009.02.010
    CrossrefPubMedGoogle Scholar
  • 2 Warrington JP, George EM, Palei AC, Spradley FT, Granger JP. Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension 2013; 62 (04) 666-673 . Doi: 10.1161/HYPERTENSIONAHA.113.00588
    CrossrefPubMedGoogle Scholar
  • 3 Lamarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol 2010; 62 (02) 105-120
    PubMedGoogle Scholar
  • 4 Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 2008; 294 (02) H541-H550 . Doi: 10.1152/ajpheart.01113.2007
    CrossrefPubMedGoogle Scholar
  • 5 Laresgoiti-Servitje E. A leading role for the immune system in the pathophysiology of preeclampsia. J Leukoc Biol 2013; 94 (02) 247-257 . Doi: 10.1189/jlb.1112603
    CrossrefPubMedGoogle Scholar
  • 6 Duhig KE, Chappell LC, Shennan AH. How placental growth factor detection might improve diagnosis and management of pre-eclampsia. Expert Rev Mol Diagn 2014; 14 (04) 403-406 . Doi: 10.1586/14737159.2014.908121
    CrossrefPubMedGoogle Scholar
  • 7 Pinheiro MB, Martins-Filho OA, Mota AP. , et al. Severe preeclampsia goes along with a cytokine network disturbance towards a systemic inflammatory state. Cytokine 2013; 62 (01) 165-173 . Doi: 10.1016/j.cyto.2013.02.027
    CrossrefPubMedGoogle Scholar
  • 8 Bewley S, Shennan A. HYPITAT and the fallacy of pregnancy interruption. Lancet 2010; 375 (9709): 119 , author reply 119–120. Doi: 10.1016/S0140-6736(10)60043-8
    CrossrefPubMedGoogle Scholar
  • 9 Lassalle P, Molet S, Janin A. , et al. ESM-1 is a novel human endothelial cell-specific molecule expressed in lung and regulated by cytokines. J Biol Chem 1996; 271 (34) 20458-20464 . Doi: 10.1074/jbc.271.34.20458
    CrossrefPubMedGoogle Scholar
  • 10 Depontieu F, de Freitas Caires N, Gourcerol D. , et al. Development of monoclonal antibodies and ELISA specific for the mouse vascular endocan. J Immunol Methods 2012; 378 (1-2): 88-94 . Doi: 10.1016/j.jim.2012.02.009
    CrossrefPubMedGoogle Scholar
  • 11 Scherpereel A, Gentina T, Grigoriu B. , et al. Overexpression of endocan induces tumor formation. Cancer Res 2003; 63 (18) 6084-6089
    PubMedGoogle Scholar
  • 12 Bechard D, Meignin V, Scherpereel A. , et al. Characterization of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000; 37 (05) 417-425 . Doi: 10.1159/000025758
    CrossrefPubMedGoogle Scholar
  • 13 Grigoriu BD, Depontieu F, Scherpereel A. , et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006; 12 (15) 4575-4582 . Doi: 10.1158/1078-0432.CCR-06-0185
    CrossrefPubMedGoogle Scholar
  • 14 Ziol M, Sutton A, Calderaro J. , et al. ESM-1 expression in stromal cells is predictive of recurrence after radiofrequency ablation in early hepatocellular carcinoma. J Hepatol 2013; 59 (06) 1264-1270 . Doi: 10.1016/j.jhep.2013.07.030
    CrossrefPubMedGoogle Scholar
  • 15 Nault JC, Guyot E, Laguillier C. , et al. Serum proteoglycans as prognostic biomarkers of hepatocellular carcinoma in patients with alcoholic cirrhosis. Cancer Epidemiol Biomarkers Prev 2013; 22 (08) 1343-1352 . Doi: 10.1158/1055-9965.EPI-13-0179
    CrossrefPubMedGoogle Scholar
  • 16 Kim JH, Park MY, Kim CN. , et al. Expression of endothelial cell-specific molecule-1 regulated by hypoxia inducible factor-1α in human colon carcinoma: impact of ESM-1 on prognosis and its correlation with clinicopathological features. Oncol Rep 2012; 28 (05) 1701-1708 . Doi: 10.3892/or.2012.2012
    CrossrefPubMedGoogle Scholar
  • 17 Kang YH, Ji NY, Han SR. , et al. ESM-1 regulates cell growth and metastatic process through activation of NF-κB in colorectal cancer. Cell Signal 2012; 24 (10) 1940-1949 . Doi: 10.1016/j.cellsig.2012.06.004
    CrossrefPubMedGoogle Scholar
  • 18 De Freitas Caires N, Legendre B, Parmentier E. , et al. Identification of a 14 kDa endocan fragment generated by cathepsin G, a novel circulating biomarker in patients with sepsis. J Pharm Biomed Anal 2013; 78−79: 45-51 . Doi: 10.1016/j.jpba.2013.01.035
    CrossrefPubMedGoogle Scholar
  • 19 Paulus P, Jennewein C, Zacharowski K. Biomarkers of endothelial dysfunction: can they help us deciphering systemic inflammation and sepsis?. Biomarkers 2011; 16 (Suppl. 01) S11-S21 . Doi: 10.3109/1354750X.2011.587893
    CrossrefPubMedGoogle Scholar
  • 20 Tadzic R, Mihalj M, Vcev A, Ennen J, Tadzic A, Drenjancevic I. The effects of arterial blood pressure reduction on endocan and soluble endothelial cell adhesion molecules (CAMs) and CAMs ligands expression in hypertensive patients on Ca-channel blocker therapy. Kidney Blood Press Res 2013; 37 (2-3): 103-115 . Doi: 10.1159/000350064
    CrossrefPubMedGoogle Scholar
  • 21 Janke J, Engeli S, Gorzelniak K. , et al. Adipose tissue and circulating endothelial cell specific molecule-1 in human obesity. Horm Metab Res 2006; 38 (01) 28-33 . Doi: 10.1055/s-2006-924973
    Article in Thieme ConnectPubMedGoogle Scholar
  • 22 Scherpereel A, Depontieu F, Grigoriu B. , et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006; 34 (02) 532-537 . Doi: 10.1097/01.CCM.0000198525.82124.74
    CrossrefPubMedGoogle Scholar
  • 23 Hentschke MR, Lucas LS, Mistry HD, Pinheiro da Costa BE, Poli-de-Figueiredo CE. Endocan-1 concentrations in maternal and fetal plasma and placentae in pre-eclampsia in the third trimester of pregnancy. Cytokine 2015; 74 (01) 152-156 . Doi: 10.1016/j.cyto.2015.04.013
    CrossrefPubMedGoogle Scholar
  • 24 Chang X, Bian Y, Wu Y, Huang Y, Wang K, Duan T. Endocan of the maternal placenta tissue is increased in pre-eclampsia. Int J Clin Exp Pathol 2015; 8 (11) 14733-14740
    PubMedGoogle Scholar
  • 25 Cakmak M, Yilmaz H, Bağlar E. , et al. Serum levels of endocan correlate with the presence and severity of pre-eclampsia. Clin Exp Hypertens 2016; 38 (02) 137-142 . Doi: 10.3109/10641963.2015.1060993
    CrossrefPubMedGoogle Scholar
  • 26 Augustin AJ. [Placenta Growth Factor (PlGF) and Retinal Vascular Diseases--Current Knowledge from Experimental and Clinical Studies]. Klin Monatsbl Augenheilkd 2016; 233 (01) 57-65 . Doi: 10.1055/s-0041-108679
    Article in Thieme ConnectPubMedGoogle Scholar
  • 27 Chappell LC, Duckworth S, Seed PT. , et al. Diagnostic accuracy of placental growth factor in women with suspected preeclampsia: a prospective multicenter study. Circulation 2013; 128 (19) 2121-2131 . Doi: 10.1161/CIRCULATIONAHA.113.003215
    CrossrefPubMedGoogle Scholar
  • 28 Report of the National High Blood Pressure Education Program Working Group on High Blood Pressure in Pregnancy. Am J Obstet Gynecol 2000; 183 (01) S1-S22 . Doi: 10.1067/mob.2000.107928
    CrossrefPubMedGoogle Scholar
  • 29 Brasileira de Cardiologia S, Brasileira de Hipertensão S, Brasileira de Nefrologia S. ; Sociedade Brasileira de Cardiologia; Sociedade Brasileira de Hipertensão; Sociedade Brasileira de Nefrologia. [VI Brazilian Guidelines on Hypertension]. Arq Bras Cardiol 2010; 95 (1, Suppl) 1-51 . Doi: 10.1590/S0066-782X2010001700001
    CrossrefPubMedGoogle Scholar
  • 30 Levine RJ, Maynard SE, Qian C. , et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350 (07) 672-683 . Doi: 10.1056/NEJMoa031884
    CrossrefPubMedGoogle Scholar
  • 31 Bates DO. An unexpected tail of VEGF and PlGF in pre-eclampsia. Biochem Soc Trans 2011; 39 (06) 1576-1582 . Doi: 10.1042/BST20110671
    CrossrefPubMedGoogle Scholar
  • 32 Reuvekamp A, Velsing-Aarts FV, Poulina IE, Capello JJ, Duits AJ. Selective deficit of angiogenic growth factors characterises pregnancies complicated by pre-eclampsia. Br J Obstet Gynaecol 1999; 106 (10) 1019-1022 . Doi: 10.1111/j.1471-0528.1999.tb08107.x
    CrossrefPubMedGoogle Scholar
  • 33 Thadhani R, Mutter WP, Wolf M. , et al. First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab 2004; 89 (02) 770-775 . Doi: 10.1210/jc.2003-031244
    CrossrefPubMedGoogle Scholar
  • 34 Munaut C, Lorquet S, Pequeux C. , et al. Hypoxia is responsible for soluble vascular endothelial growth factor receptor-1 (VEGFR-1) but not for soluble endoglin induction in villous trophoblast. Hum Reprod 2008; 23 (06) 1407-1415 . Doi: 10.1093/humrep/den114
    CrossrefPubMedGoogle Scholar
  • 35 Osol G, Celia G, Gokina N. , et al. Placental growth factor is a potent vasodilator of rat and human resistance arteries. Am J Physiol Heart Circ Physiol 2008; 294 (03) H1381-H1387 . Doi: 10.1152/ajpheart.00922.2007
    CrossrefPubMedGoogle Scholar
  • 36 Schuitemaker JHN, Cremers TIFH, Van Pampus MG, Scherjon SA, Faas MM. Changes in endothelial cell specific molecule 1 plasma levels during preeclamptic pregnancies compared to healthy pregnancies. Pregnancy Hypertens 2018; 12: 58-64 . Doi: 10.1016/j.preghy.2018.02.012
    CrossrefPubMedGoogle Scholar